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Abstract
Presented work focuses on the development of biodegradable polymer nanoparticles loaded with antibiotics as drug delivery
systems deposited on electrospun scaffolds for tissue engineering. The innovative ciprofloxacin-loaded poly(DL-lactide-co-
glycolide) NPs ensure a continuous slow release and high local concentration at the site of action for an optimal therapy. The
local delivery of antibiotics as an integrated part of electrospun scaffolds offers an effective, safe, and smart enhancement
supporting tissue regeneration. Presented data provides solid scientific evidence for fulfilling the requirements of local nano
antibiotic delivery systems with biodegradability and biocompatibility for a wide range of tissue engineering applications,
including middle ear tissues (e.g., tympanic membranes) which are subject to bacterial infections. Further characterization of
such systems, including in vivo studies, is required to ensure successful transfer from lab to clinical applications.
Keywords Nanoparticles . Electrospinning . Stem cells . Immunomodulation . Regenerative medicine
Introduction
Nano drug delivery systems are being intensively investigated
due to the increasing demand on safer, more effective, and
lower-cost drug formulations. Nanomedicine has rapidly pro-
moted the development of a large number of new-generation
innovative products that reached clinics [1]. A variety of dif-
ferent approaches from polymeric to inorganic nanoparticles
(NPs) and lipid to liposome based have been developed as
nano drug carriers [2, 3]. Among them, the (bio)polymer-
based NP systems are highly accepted and have already
shown clinical success. However, there remain several unre-
solved challenges in integrating these successful drug delivery
systems with the emerging fields of regenerativemedicine and
tissue engineering (TE).
With the ability to repair damaged or defunct tissues, TE has
evolved as a promising approach towards addressing the cur-
rent lack of sufficient implantable tissues and organs.
Introduced in the late 1980s, TE aims at applying the principles
of engineering and life sciences to develop biological substi-
tutes that can restore, maintain, or improve tissue functionality
[4]. There are three key pillars identified for the application of
TE-based approaches, which are (a) supporting scaffolds, (b)
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bioactive molecules, and (c) incorporation of cells. Among
these, the development of relevant three-dimensional (3D) scaf-
folds has been deemed crucial for mimicking the native tissue
architecture and properties [4]. Biofabrication has emerged as
an essential toolkit for the automated generation of 3D con-
structs loaded with requisite bioactive molecules for replicating
the tissue microenvironment [5]. These 3D biofabricated scaf-
folds ladenwith essential growth factors are then used to culture
cells, before they can be grown into a full tissue and
transplanted into the human body. Latest strategies, such as
3D bioprinting have even advocated the incorporation of cells
during the fabrication process, but their discussion is beyond
the scope of this work [6].
Electrospinning (ES) is a widely used biofabrication tech-
nique for manufacturing polymeric fibers within the range of
native collagen fibrils [7, 8]. Electrospun fibers, with both
synthetic and natural polymers, have been reported to be ex-
cellent candidates for manufacturing tissue-engineered scaf-
folds for several applications, such as regeneration of the tym-
panic membrane [9, 10], skin [11], and cartilage [12], among
other tissues. Many of these synthetic biodegradable polymers
with non-toxic character have been found to be promoting
superior cell attachment and proliferation, with modulated in-
flammatory response. Moreover, therapeutic molecules are
also known to play a vital role in the regeneration of damaged
tissues [13]. Tissue implants of electrospun fibers loaded with
various drugs and/or biomolecules have been shown to en-
hance the regenerative properties by facilitating the local de-
livery of these entities [14–17]. However, the lack of a suitable
microenvironment, for example, due to the presence of an
infection on-site may affect the implants’ biocompatibility
and jeopardize their regenerative properties.
Electrospun scaffolds loaded with antibiotic nanoparticles,
on the other hand, can offer several advantages [18], since they
provide controlled and sustained release of antibiotics at effec-
tive concentration at local site to actively prevent infection and,
eventually, the biofilm formation after implantation and during
healing. Incorporating antibacterial agents in electrospun scaf-
folds might not only prevent infection during wound healing
but also may prevent rejection of the implant due to minimized
stress at microenvironment as a result of sustained and con-
trolled release of the agent. Controlling the release kinetics of
drug and biomolecules from the electrospun fibers is critical in
regenerative tissue engineering [15, 19]. Different methods
have been used to incorporate antimicrobial agents in
electrospun fibers during the ES process, including blending
[6], coaxial ES [6], and emulsion ES [6], to provide controlled
release of the agent [20]. All these strategies result in the en-
capsulation of the antibiotic within the electrospun fibers, where
its release is directly dependent on the degradation of the poly-
meric nanofibers. These approaches usually employ a relatively
fast degrading polymer to achieve a sustained release of the
antibiotic [21–23]. However, several applications in TE, such
as bone, cartilage, and tympanic membrane, often demand the
use of polymers that could remain stable at least for a few
months [24, 25]. Therefore, the abovementioned ES strategies
might not be suitable for these applications. To address this
issue, we have developed a co-ES/electrospraying setup to load
antibiotic-loaded NPs on the surface of polymer scaffolds.
In this study, ciprofloxacin-loaded poly(DL-lactide-co-
glycolide) (PLGA) and poly(ε-caprolactone) (PCL) NPs depos-
ited on electrospun fibers are developed and characterized for
their potential use in tissue engineering. These systems are
aimed to have anti-inflammatory and antimicrobial activity
with biocompatible drug delivery system character. The poly-
meric nanoparticles which are prepared from biocompatible
and biodegradable polymers, like PLGA and PCL, have shown
significant therapeutic potential to achieve controlled drug de-
livery [26–31]), where the drug release was modified by alter-
ing the psychochemical properties, and formulation compo-
nents, as well as by optimizing different preparation techniques
[32]. For this purpose, modified solvent evaporation-double
emulsion water-in-oil-in-water (w/o/w) and nanoprecipitation
approaches are evaluated for manufacturing ciprofloxacin-
loaded PLGA and PCL nanoparticles using continuous
microjet reactor technology [26, 33, 34]. Nanoparticulate sys-
tems are designed to provide prolonged delivery in a controlled
way to enhance therapy and increase patient compliance.
This work proposes the use of a co-electrospinning/
electrospraying approach as the suitable biofabrication tech-
nique to evaluate the incorporation of ciprofloxacin-
encapsulated NPs on tissue-engineered scaffolds.
Poly(ethylene oxide terephthalate)/poly(butylene terephthal-
ate) (PEOT/PBT) copolymer was used to construct the NP-
loaded electrospun scaffolds. Two independent strategies were
investigated for a homogeneous deposition of the NPs.
To our best knowledge, none of the current devices clinically
employed for regenerative medicine and TE are based on bio-
mimetic features with nanoscale resolution, and none of them
rely on the application of nanotechnology. We aim developing
and demonstrating the proof of concept for novel implants com-
bining nanomedicine and tissue engineering in a single multi-
functional platform in order to overcome the current therapy
bottlenecks. We present the potential use of electrospun scaf-
folds that enable safe and efficient tissue engineering with a low
risk of adverse events and rejections due to reduced bacterial
infection and biofilm owing to local antibiotic delivery via em-
bedded innovative, biodegradable NP formulations.
Materials and methods
Materials
PLGA (5050 DLG 4A, 52 kDa) and poly(ε-caprolactone)
(100 CL 4E-HD, 31 kDa) were both obtained from Evonik
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(Birmingham, AL, USA). Ciprofloxacin was purchased from
Sigma-Aldrich (Steinheim, Germany), and ciprofloxacin HCl
was purchased from AppliChem (Darmstadt, Germany).
Sorbitan monooleate (Span® 80; Guangdong Runhua
Chemistry Co., Ltd., China), polyethylene glycol sorbitan
monooleate (Tween® 80; VWR, Darmstadt, Germany), poly-
vinyl alcohol (PVA, Mowiol® 4-98; Sigma-Aldrich,
Steinheim, Germany), and D-alpha-tocopheryl polyethylene
glycol 1000 succinate (Vitamin E TPGS; Gustav Parmentier
GmbH, Frankfurt, Germany) were used as surfactants. Oleic
acid (Ph. Eur.), acetone, chloroform, hexafluoroisopropanol,
and ethyl acetate were purchased from VWR (Darmstadt,
Germany). Copolymer of PEOT/PBT was kindly provided
by PolyVation B.V. (Groningen, The Netherlands). Being a
segmented random block copolymer, its soft, hydrophilic
PEOT segments are physically cross-linked by the hard,
semi-crystalline PBT segments. The selected composition of
PEOT/PBT for this study was 300PEOT55PBT45, where fol-
lowing an aPEOTbPBTc classification, the number 300 sig-
nifies the molecular weight (Mw, g/mol) of the initial PEG
blocks used in the copolymerization, whereas 55/45 are the
weight ratios of PEOT and PBT blocks, respectively.
Human mesenchymal stem cells (hMSCs) were supplied
from Merck Millipore S.A.S. (Burlington, MA, USA).
Human immortalized dermal keratinocyte HaCaT, L-gluta-
mine, penicillin, streptomycin, and fetal calf serum were pur-
chased from Invitrogen (Carlsbad, CA, USA). Fetal bovine
serum (FBS) and LIVE/DEAD kit were bought from
Thermo Fisher Scientific (Waltham, MA, USA). Resazurin,
Dulbecco’s minimal essential medium (DMEM), phosphate-
buffered saline (PBS), gentamycin sulfate, and Triton-X were
supplied by Sigma (Milan, Italy). Bacteria Staphylococcus
aureus (ATCC 6538) and Pseudomonas aeruginosa (ATCC
9027), as well their culture substrates (tryptic soy (TS) agar
and Luria-Bertani (LB) agar, respectively) were obtained from
ATCC (Manassas, VA, USA).
NP preparation with nanoprecipitation method
Bench-top nanoprecipitation method was modified after Torge
et al. [35]. Briefly, 4 mg/ml PCL or PLGA and 1.5 mg/ml Span
80® solution in acetone was mixed with 165 μl of 48.5 mg/ml
ciprofloxacin solution in oleic acid to obtain the solvent system.
Blank nanoparticles were prepared without ciprofloxacin, by
only adding oleic acid into the solvent. Ciprofloxacin-
containing solutions were protected from light; 0.15% aqueous
Tween 80 solution was used as a non-solvent system for both
PLGA and PCL NP preparations. Solvent system was trans-
ferred on the non-solvent system at 1:2 v/v ratio under contin-
uous stirring. NPs were protected from light.
NP preparations via the nanoprecipitation method by uti-
lizing continuous microjet reactor (MJR) technology was per-
formed at 25 °C where solvent delivering capillaries and the
MJR were immersed into a water bath in order to control the
system temperature. Solvent system and non-solvent system
were delivered to the MJR at 1:2 flow rate ratio at 180° angle
by using Smartline S100 pumps (Knauer, Munich, Germany).
Since nitrogen gas was not employed, fourth opening was
sealed.
Removal of organic phase and purification was achieved
by continuous flow filtration (CFF) where modified polye-
thersulfone (mPES) MidiKros® 0.5-mm hollow fiber filters
with a 10 kDa MWCO and a surface area of 235 cm2
(Spectrum; Repligen Europe B.V., Breda, Netherlands) were
used. For biofabricated electrospun scaffolds containing NPs,
ciprofloxacin-loaded NPs were concentrated 5-fold by using
CFF to obtain higher ciprofloxacin concentrations during op-
timization of biofabrication of the scaffolds.
For preparation of metallic core loading in PLGA via
nanoprecipitation, please refer to supplementary materials.
PLGA NP preparation with modified w/o/w method
Organic solvent–containing phase was prepared by dissolving
PLGA in ethyl acetate to obtain 20 mg/ml of polymer concen-
tration. Thereafter, ciprofloxacin HCl (35 mg/ml) dissolved in
an aqueous solution of 1% PVA was emulsified with PLGA
solution at 1:3 v/v ratio. Emulsification was performed with a
WiseTis® HG-15A homogenizer at 27,000 rpm for 30 s.
Directly after primary emulsion was obtained, second emulsi-
fication was performed at 27,000 rpm for 1 min, where aque-
ous 2% Vitamin E TPGS solution was used as dispersing
phase at 1:5 v/v ratio. The final formulation was obtained by
adding on an aqueous solution of 1% TPGS solution under
moderate stirring at 1:2 v/v ratio. NPs were protected from
light during evaporation of organic phase under stirring.
Blank NPs were prepared without ciprofloxacin HCl, only
with 1% PVA solution in the primary emulsion.
NP preparations by utilizing MJR technology was per-
formed at 25 °C where solvent delivering capillaries and the
MJR were immersed into a water bath in order to control the
system temperature. For preparation of the primary emulsion,
inner phase and organic solvent were delivered to the MJR at
1:3 flow rate ratio at 180° angle by using Smartline S100
pumps (Knauer, Munich, Germany). Then, the MJR was run
in loop mode for 10 cycles. Primary emulsion was mixed with
outer phase by MJR at 1:5 flow rate ratio and homogenized at
loop mode for 20 cycles. Since nitrogen gas was not
employed, fourth opening was sealed. Double emulsion was
added on 1% TPGS solution under moderate stirring.
Removal of organic phase, purification, and, where neces-
sary, concentration were achieved as stated for the
nanoprecipitation method.
For preparation of metallic core (gold and iron oxide NP)
loading in PLGAvia the modified w/o/w method, please refer
to supplementary materials.
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Physicochemical characterization of nanoparticles
The methods for particle size distribution, zeta potential deter-
mination, ciprofloxacin quantification, encapsulation efficien-
cy (EE) %, and drug loading (DL) % determination, as well as
in vitro release testing, are provided in supplementary
materials.
The feasibility testing method of down processing of NPs
into scaffolds is also provided in supplementary materials.
Electrospinning and electrospraying of the scaffolds
300PEOT55PBT45was used as the selected PEOT/PBTcom-
position. A polymeric solution with 18% (w/v) of
300PEOT55PBT45 was prepared in a 70:30 solvent mixture
of chloroform and hexafluoroisopropanol (HFIP), respective-
ly. In the first approach, prefabricated electrospun meshes
were immersed in NP solutions and left overnight at room
temperature. The second approach, being the more sophisti-
cated of the two, implemented a co-ES/electrospraying (co-
ES/E) setup for simultaneous deposition of NPs during the ES
process. The ES parameters for PEOT/PBT were maintained
consistent for both the immersion and co-E/E approaches. A
voltage of 20 kV was applied between the spinneret and
grounded mandrel (diameter = 20 cm) rotating at 150 rpm.
The flow rate for polymer extrusion was set at 0.9 ml/h with
a working distance of 10 cm. In addition to these, for the co-E/
E approach, a supplementary spinneret was installed perpen-
dicularly for the simultaneous electrospraying of NP solution.
The flow rate for NP extrusion was optimized at 1.5 ml/h for a
working distance of 5 cm.
Volatile solvent systems employing EtOH andMeOHwere
investigated for the predominantly aqueous NPs to enhance its
rate of evaporation during electrospraying. A metallic core
(gold and iron) was introduced within the NPs (see supple-
mentary material for further details) to ameliorate their imag-
ing under scanning electron microscope (SEM) and transmis-
sion electron microscope (TEM). Finally, Au-PLGA NPs in
water was used as a proof of concept for this study.
The adhesion of PLGA NPs deposited on top of the
electrospun fibers was evaluated for 24 h, 48 h, and 72 h.
Samples were immersed in Milli-Q water at room tempera-
ture, collected, dried, and analyzed by SEM.
In vitro characterization
Cytotoxicity tests
Cytotoxicity tests were carried out by using hMSCs and
HaCaT cell line. The different nanoparticles, both plain and
ciprofloxacin loaded, including ciprofloxacin powders (base
and HCl) and untreated cells as controls, were used. All cell
culture studies were carried out in a humidified incubator at
37 °C in air and 5% CO2/95% air environment.
HaCaT cells were seeded at 250,000 cells/well in 12-well
culture plates added with DMEM supplemented with 1% Pen-
Strep, 1% glutamine, and 10% fetal calf serum for 24 h. PLGA
produced with microprecipitation (PLGA-microP); PLGA
produced with water-in-oil-in-water emulsion (PLGA-wow),
PCL, and blank NPs, as well as ciprofloxacin powders; and
different dilutions obtained from 200 μg/ml stock solutions
were administered to the cells, namely 1:2, 1:5, 1:10, 1:100,
1:1000, and 1:10,000, leading to 100 μg/ml, 40 μg/ml,
20 μg/ml, 2 μg/ml, 0.2 μg/ml, and 0.02 μg/ml concentrations,
respectively.
HMSCs were seeded at a 25,000 cells/well in 24-well cul-
ture plates and cultured using 1 ml/well of DMEM low glu-
cose supplemented with 2 mM L-glutamine, 100 IU/ml peni-
cillin, 100 mg/ml streptomycin, and 10% heat-inactivated
FBS for 48 h (n = 3). The final ciprofloxacin amount in each
sample treated with ciprofloxacin-loaded nanoparticles and
powder was 20 μg/ml.
Resazurin dye test was used to assess the metabolic activity
of HaCaT cells and hMSCs at their endpoints and was per-
formed under UV-vis spectrophotometry. Briefly, resazurin
was dissolved in PBS at 0.5mg/ml and sterile filtered to obtain
a stock solution. At the endpoint, the culture media were re-
moved and replaced with culture media conditioned with
resazurin and let react for 3 h in incubator. Resazurin turns
from blue into purple-pink as a consequence of cellular reduc-
tion. After, the supernatant was removed and read in a plate
reader (Victor 3; PerkinElmer, Waltham, MA, USA) using a
double wavelength reading (at 570 nm and 600 nm). The
percentage of dye reduction with respect to controls was cal-
culated by taking into account the molar extinction molar
coefficients of the dye at the two wavelengths.
For HaCaT cells, the samples were assayed in duplicate
(n = 2) against negative controls (samples without cells) and
data are reported as average.
For hMSCs, the samples were assayed in triplicate (n = 3)
and each sample was run 3 times. The absorbance data were
normalized positive controls (untreated cells), and data were
given as mean ± standard deviation. Statistical analysis was
performed for different subgroups using Student’s t test for
independent samples. Statistical significance was assessed for
p values < 0.05 by taking into account Bonferroni’s correction.
At the endpoint, LIVE/DEAD assay was used to specifi-
cally identify dead hMSCs under fluorescence microscopy
(Nikon Ti, Tokyo, Japan) equipped with a digital camera.
Briefly, 2 μM ethidium homodimer 1 in PBS was added to
the cells, incubated for 30 min in incubator, and analyzed
under TRITC. Micrographs were acquired for each group at
× 20 magnification.
For evaluating the cytocompatibility of electrospun scaf-
folds with and without ciprofloxacin-loaded PLGA
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nanoparticles, hMSCs were seeded (250,000 cells/scaffold)
and cultured up to 8 days. Two time points (day 1 and day
8) were chosen for assessing the growth and proliferation of
the seeded cells, which was performed by staining the actin
filaments of the cells using Alexa Fluor™ 488 phalloidin
(Thermo Fisher Scientific, Waltham, MA, USA), and nuclei
using 4,6-diamideino-2-phenylindole dihydrochloride (DAPI;
Sigma-Aldrich, St. Louis, MO, USA). The 1:100 and 1:1000
dilutions of the reagents were used, respectively.
Bacterial activity tests
Strains of S. aureus and P. aeruginosa were grown overnight
in the appropriate culture media. The broth cultures obtained
after overnight incubation were diluted at a concentration of
0.5 O.D., and 100 μl of each was plated on agar medium with
the help of a swab. Following sowing, holes were drilled on
the plates in which 100 μl of each substance was added at
different dilutions, namely undiluted (T.Q.), 1:10, 1:100,
1:500, and 1:1000, leading to 200 μg/ml, 20 μg/ml,
2 μg/ml, 0.4 μg/ml, and 0.2 μg/ml concentrations, respective-
ly. An antibacterial activity is revealed by the presence of a
transparent zone around the holes, due to the inhibition of
bacterial growth. The diameters of the zones were measured
and compared after 18 h of inoculation.
Bacterial adhesiveness and internalization assays
For adhesiveness assay, semi-confluent monolayers of HaCaT
cells (80,000 cells in 48-well plate) were grown overnight in
DMEM, washed, and infected with exponentially growing
S. aureus or P. aeruginosa with or without samples at 37 °C
in 5% CO2 for 2 h.
At the end of this time, infected monolayers were washed
three times with PBS medium to remove non-adherent bacte-
ria. The total number of cell-associated bacteria was deter-
mined by lysing the monolayers with 0.1% Triton X-100.
Solubilized bacteria were counted (colony-forming units
(CFUs)) by spreading serial dilutions on TSA or LB agar
plates, respectively, and incubating at 37 °C overnight.
Adhesion efficiency was calculated as the ratio of the number
of cell-associated bacteria and the number of bacteria used to
infect cell monolayers.
In the internalization assay, the cells, infected as previously
described, were extensively washed and further incubated for
1.5 h with fresh medium supplemented with gentamicin sul-
fate (250 μg/ml) in order to kill extracellular bacteria. At the
end of this time, monolayers were washed with PBS, lysed
with 0.1% Triton X-100, serially diluted, and plated on LB
agar to quantify viable intracellular bacteria (CFU/ml). The
efficiency was calculated as the ratio of the number of cell-
internalized bacteria and the number of bacteria used to infect
the cell monolayers.
Results
Physicochemical characterization of nanoparticles
Blank NPs prepared by both modified w/o/w and
nanoprecipitation methods via bench-top approach were
smaller than 250 nmwith moderate PDI values < 0.2, whereas
ciprofloxacin-loaded bench-top NPs were slightly larger in
size with PDI values < 0.25. MJR is a micromixer with con-
fined impinging jet principle, where NPs are formed under
controlled process conditions. Microvolume mixing at short
mixing times leads to narrow particle size distributions (thus,
lower PDI values) owing to continuous mixing in a
microvolume [26, 34]. Indeed, this was observed for all cases,
where PDI values for both blank and ciprofloxacin-loaded
particles were < 0.15 regardless of the employed manufactur-
ing method. All formulations showed negative zeta potential
(Table 1). Optimization studies revealed that MJR process
parameters (flow rate, temperature, and pressure) had a signif-
icant effect on the particle size of ciprofloxacin-loaded PLGA
and PCL NPs regardless of the employed method.
Furthermore, the difficulties in scale-up are overcome by
using a microjet reactor for continuous production with easily
controllable parameters and reproducible results [36–38],
whereas EE % and DL % were dominantly affected by for-
mulation properties (drug:polymer ratio and solvent:non-sol-
vent ratio). As the drug:polymer and solvent:non-solvent ra-
tios decreased, the EE % increased but the particle size was
not significantly affected. Additionally, in order to enhance
drug loading, oleic acid was used as co-solvent for dissolving
ciprofloxacin [35, 39]. Furthermore, ciprofloxacin has amine
and carboxylic acid functional groups, which can interact with
oleic acid by forming counter ion complexes [40]. Indeed, EE
% of ciprofloxacin-loaded PLGA particles prepared by double
emulsion method was determined as 60.7% (n = 3), whereas
ciprofloxacin-loaded PCL NPs had 82.7% EE (Fig. 2). By
analyzing both permeate and retentate after centrifuging the
samples with Macrosep® centrifugal device, the mass balance
showed that there was no loss due to entrapment or deposition
on the membrane. Additionally, ciprofloxacin solution was
used as control for the filter compatibility testing to conclude
that the ciprofloxacin did not show any interaction with the
centrifugal device.
Particles were shown to be stable after 30 days of stability
studies in room temperature as shown in Figs. 1 and 2. Long-
term stability studies are ongoing.
Release study
Ciprofloxacin was released from PLGA-wow over 24 h fol-
lowing the Korsmeyer-Peppas kinetic model [41], which in-
dicated anomalous release (n = 0.6). Anomalous release from
PLGA is defined by Fick`s diffusion followed by polymer-
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driven release. Similarly, to PLGANPs, no initial burst release
was observed for PCLNPs (< 30%within the first 1 h). On the
other hand, ciprofloxacin release from PCL reached ca. 60%
after 24 h and the release was completed in 2 weeks (94.6%,
data not shown). No burst release was observed (< 30%within
the first 1 h). Slower release kinetics from the PCL NPs is
possibly due to the interaction of ciprofloxacin with oleic acid.
Results provided as an average cumulative released amount of
ciprofloxacin as percentage over time are depicted in Fig. 3.
Biofabrication of NP-loaded electrospun scaffolds
Electrospinning has emerged as an essential biofabrication
strategy for constructing polymeric fibers within the range of
native collagen fibrils. Owing to its simple yet robust technol-
ogy, electrospun scaffolds have been manipulated for several
tissue engineering applications. However, following success-
ful transplantation of these tissue-engineered grafts or organs,
targeted delivery of antibiotics has remained a major chal-
lenge. In this study, the incorporation of drug-loaded NPs on
electrospun scaffolds was investigated as a proof of concept
using Au-PLGANPs. The gold core was chosen over iron due
to its more uniform morphology and distribution as observed
under TEM (Fig. 4). Preliminary studies with volatile
electrospraying solvent systems did not yield any improve-
ment in the fiber morphology; therefore, water was chosen
as the working solution for NPs. Finally, both modified w/o/
w and nanoprecipitation were evaluated as potential synthesis
routes for the two incorporation strategies highlighted in the
previous section.
The immersion strategy for double emulsion NPs demon-
strated deposition of some spherical aggregates over the
electrospun nanofibers, accompanied by a widespread film
enveloping them (Fig. 5b). On the other hand, the same ap-
proach for nanoprecipitated NPs did not result in any film
formation. However, these NPs were observed only in large
clusters, randomly spread over the immersed scaffold
(Fig. 5c).
A similar trend concerning the film was observed in the
case of co-E/E approach. Surprisingly, it persisted for double
emulsion NPs even during its simultaneous deposition
(Fig. 5e). Different concentrations of NP solution were tested
to get rid of the film, but without any success. However, in
terms of the deposition efficacy, co-E/E fared far better than
the immersion strategy. Comparatively smaller and more ho-
mogeneous NP aggregates were obtained for double
Table 1 Physicochemical characterization of NPs
Nanoprecipitation Double emulsion/solvent evaporation method
Bench-top MJR Bench-top MJR
PS
(nm)
PDI ZP
(mV)
EE
(%)
PS
(nm)
PDI ZP
(mV)
EE
(%)
PS
(nm)
PDI ZP
(mV)
EE
(%)
PS
(nm)
PDI ZP
(mV)
EE
(%)
Blank PLGA NPs 105.3 0.152 − 34.6 – 99.6 0.089 − 34.9 – 242.5 0.186 − 33.2 – 215.6 0.102 − 38.4 –
Ciprofloxacin-loaded
PLGA NPs
108.6 0.179 − 30.5 60.7 102.2 0.075 − 28.6 64.4 226.2 0.211 − 30.8 72.4 222.5 0.115 − 32.2 74.1
Blank PCL NPs 209.0 0.079 − 48.2 – 195.4 0.034 − 47.3 –
Ciprofloxacin-loaded
PCL NPs
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emulsion, whereas in the case of nanoprecipitated batch, indi-
vidual NPs were deposited on the nanofibers across the entire
scaffold, thereby emerging as the most optimum system for
incorporation of drug-loaded NPs onto electrospun network
(Fig. 5f).
Following the desired deposition, a successful adhesion
was confirmed by submerging the NP-loaded scaffolds in
Milli-Q water. SEM micrographs obtained at 24 h, 48 h, and
72 h demonstrated a similar distribution of NPs over time
(Fig. 6). The same experiment was also repeated with the
double emulsion NPs to study its influence on the film.
However, no change was observed.
Down-processing feasibility
In addition to the release from the encapsulationmaterial, fiber
composition containing antibiotic-loaded NPs for a controlled
and sustained delivery should be carefully investigated. The
diffusion of drug is directly influenced by the polymer prop-
erties. Therefore, the composition of nanofibers and the dis-
tribution of NPs over them are crucial for achieving desired
drug release profiles. Additionally, the miscibility and stability
of NPs during the biofabrication process also plays a critical
role. To minimize the influence of an additional solvent
enveloping the rotating collector ES PEOT/PBT, systems with
higher volatility were investigated for the NPs. In order to
ensure that the particles were intact and no drug release oc-
curred upon dispersion in these new solvent systems, NPs
were exposed and incubated with potential organic solvents
that were applied for the preparation of drug-loaded nanofi-
bers. Dose dumping studies showed that the particles were
stable in all of the test solutions, where particle sizes were
not affected and PDI values were comparable after 24 h. As
shown in Fig. 6, the PCL particles (Fig. 7a) and PLGA parti-
cles (Fig. 7c) showed similar profiles compare to control (NPs
dispersed in water). On the other hand, for the concentrated
PCL nanoparticles (Fig. 7b), the dose dumping test sample
with EtOH addition showed a particle size change of approx-
imately 35 nm after 24 h where all the other samples were
shown to have similar particle size and PDI. Considering that
most particle size measurements are associated with ca. 50 nm
measurement uncertainty, one can neglect that change in hy-
drodynamic diameter.
Additionally, at predefined time points for determination of
free ciprofloxacin, HPLC analysis was performed for all the
samples of PCL and PLGA NPs where supernatants were
injected following separation of the particles from released/
dumped free drug in triplets. Figure 8 a shows PCL
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nanoparticles determined to have the highest amount of cip-
rofloxacin released in the presence of EtOH after 24 h where
other solvents showed similar profiles compare to blank par-
ticles with water.
In vitro characterization
Cytotoxicity
The metabolic activity of HaCaT cells and hMSCs after ad-
ministration of the NPs was investigated using the resazurin
test. HaCaT cells were treated with different doses (ranging
from 20 ng/ml to 100 μg/ml) of ciprofloxacin-loaded (C+)
PLGA-NPs, PLGA-wow and PCL NPs, blank (C−) NPs,
and free drug ciprofloxacin for 24 h. The results of cell met-
abolic activity are summarized in Fig. 9. Keratinocytes had a
drop in their viability (< 50%) when treated with NPs at cip-
rofloxacin concentrations ≥ 20 μg/ml, whereas ciprofloxacin
concentrations ≤ 2μg/ml were tolerated well and did not show
any cytotoxicity. These results were consistent with the blank
NPs of each particles applied at the same ciprofloxacin equiv-
alent concentrations with the exception of blank PLGA-NPs,
where no cytotoxic effect was exerted by blank NPs. These
results lead to the assumption that the cytotoxicity was not
depending on the ciprofloxacin concentration for PLGA-
wow and PCL NPs but any potential presence of cytotoxic
components in NPs regardless of the preparation method or
possibly the stress exerted to the cells by the presence of
colloidal systems. Both assumptions were in accordance with
the results obtained from free drug ciprofloxacin.
Based on the preliminary cytotoxicity test on HaCaT cells,
the test concentration for hMSCs was assigned as 20 μg/ml.
hMSCs were exposed to NPs for 48 h in order to assess the
possible cytotoxic effects. Figure 10 shows the results of
resazurin test where the metabolic activity of ciprofloxacin-
loaded (C+) NPs was 79.0% ± 5.6% for PCL, 84.2% ± 4.3%
for PLGA-NPs, and 84.9% ± 4.9% for PLGA-wow. When
applied at this concentration for a prolonged time (48 h),
ciprofloxacin-loaded NPs showed statistically significant re-
duction with respect to the free ciprofloxacin base (Fig. 10a–
c). In each group, the presence of ciprofloxacin (C+) in NPs
led to a decrease of metabolic activity, which was statistically
significant in PLGA NPs (p < 0.01) and in PCL (p < 0.0001)
(Fig. 10a, c) but not in PLGA-wow (p = 0.05, not significant)
(Fig. 10b). It was concluded that ciprofloxacin-loaded NPs
were not showing any cytotoxic effects on hMSCs when ap-
plied at 20 μg/ml concentrations even at prolonged exposure.
These findings were qualitatively confirmed by the
ethidium homodimer 1 (DEAD) test under fluorescence mi-
croscopy (supplementarymaterial Figure S1).More dead cells
stained in red were visible in the C+ NP–treated hMSCs in
comparison to C− NP–treated cells.
Phalloidin/DAPI staining of the hMSCs seeded on the
electrospun scaffolds with ciprofloxacin-loaded PLGA NPs
showed a homogeneous cell distribution and attachment, sim-
ilar to that of the control on day 1 (Fig. 11). After 8 days in
culture, the electrospun scaffolds containing ciprofloxacin-
loaded PLGA nanoparticles did not show any noticeable ef-
fect on cellular growth and proliferation, when compared with
control.
Under the light of cytotoxicity tests, it was concluded that
all of the prepared formulations were non-toxic and well tol-
erated even for concentrations up to 20-fold exceeding mini-
mum inhibitory concentration (MIC) of ciprofloxacin against
susceptible and resistant strains of P. aeruginosa (0.25–
0.99 μg/ml)1.
Bactericidal activity, adhesiveness, and invasion test
The results of S. aureus inhibition showed that, in particular, at
a concentration of 20 μg/ml, all the ciprofloxacin-loaded NPs
outperformed the free drug ciprofloxacin activity (see S2 A–F
for details), where PLGA-wow and PCL-NPs showed slightly
better bactericidal activity than PLGA-NPs (Fig. 12). PLGA-
wow was shown to be the most efficient NP against S. aureus
at concentrations even at reduced concentrations of 2 μg/ml
and 0.4 μg/ml.
The results of P. aeruginosa inhibition as obtained with
zone diameter measurements (see S3 A–F for details) after
1 Breakpoint tables for interpretation of MICs and zone diameters, in the
European Committee on Antimicrobial Susceptibility Testing, 2014.
Fig. 4 TEM micrographs of PLGA NPs synthesized with metallic core (Au and Fe). a Modified w/o/w. b Nanoprecipitation
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treatment with NPs are reported in Fig. 13. At all concentra-
tions (0.2–200 μg/ml), the NPs did inhibit P. aeruginosamore
effective than free ciprofloxacin. All the NPs did inhibit
P. aeruginosa even at 2 μg/ml concentration, where free drug
did not show effective inhibition. PLGA-wow and PCL still
showed inhibitory effects even at 0.4 μg/ml concentration.
Blank NPs were tested as controls against both S. aureus
and P. aeruginosa. Results indicated that blank NPs do not
show any inhibitory effect (data not shown).
Finally, bacterial adhesion and invasion tests were per-
formed by infecting HaCaT cells treated with the
ciprofloxacin-loaded and blank NPs. The results showed that
all ciprofloxacin-loaded NPs were able to hamper S. aureus
adhesion (Fig. 14a), in particular PCL NPs showed the best
inhibition percentage (− 60%). S. aureus invasion to HaCaT
cells was inhibited by all of the tested ciprofloxacin-loaded
NPs. The same observation was done for P. aeruginosa inva-
siveness and adhesion (about − 100%) (Fig. 14b). Not surpris-
ingly, blank NPs did not exert any effects, except for PCL
NPs, which acted similarly to loaded NPs (− 100% invasive-
ness and − 80% adhesion).
Discussion
In many tissue engineering applications, the role of the scaf-
fold is to support healthy tissue regrowth, which comes after
reconstructive surgery in a hostile microenvironment, in
which inflammation is present, together with high probability
of infection relapses. This is the case of tissues which usually
Fig. 6 SEMmicrographs confirming the adhesion of PLGANPs onto the electrospun fibers, when left immersed inMilli-Qwater for 24 h, 48 h, and 72 h
in ambient conditions. Scale bars: normal = 5 μm, magnified inset = 1 μm
Fig. 5 Incorporation of antibiotic-loaded PLGA nanoparticles with sim-
ple immersion approach (a–c) and simultaneous co-electrospinning/
electrospinning approach (d–f). a, d Schematics representing the two
approaches. b, e Incorporation of wow NPs. c, f Incorporation of
nanoprecipitated NPs. Scale bar = 5 μm
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deal with microbiome and pathogens, like epithelia (e.g., ear,
oral cavity, airways, skin, intestine, urinary tract). In order to
enable a satisfactory regeneration of these tissues, it is of max-
imal importance to have non-contaminated tissue healing and
tissue regeneration. Therefore, the possibility of having a
combined platform enabling both antibiotic release and tissue
regeneration offers remarkable advantages in engineering ear,
airways, skin, and oral tissues, among others. S. aureus and
P. aeruginosa are two common bacteria affecting the respira-
tory tract, which can overgrow, leading to chronic, recalcitrant
infections caused by biofilm formation [42, 43]. The use of
NPs locally for promoting non-contaminated tissue healing
and tissue regeneration offers many advantages such as (i)
enhanced bioavailability, thus reduced doses, and potentially
decreased side effects; (ii) sustaining the concentration at the
site of action, thus potentially reduced application frequency;
and (iii) achieving homogenous drug dose distribution across
the tissue to heal.
In this study, we tested the safety and efficacy of NPs
against these bacteria, where the proof-of-concept studies
were realized by using employing different polymers as en-
capsulation materials for ciprofloxacin delivery. PLGA-
encapsulated pharmaceutical products are already at the mar-
ket for some years and have been well characterized. Since
PLGA possesses low toxicity, biocompatible character, and
predictable biodegradation kinetics, it is extensively employed
for drug delivery purposes [44]. PCL is a biodegradable poly-
mer which belongs to aliphatic polyester family and has been
extensively used for the development of wound dressings,
contraceptive devices, fixation devices, and drug delivery sys-
tems [45–47]. Both of these polymers offer marketable drug
delivery systems since they are very well characterized for
safety and performance, and they are non-toxic polymers with
biodegradable character. Indeed, careful selection of not only
encapsulation material but also other formulation components
(excipients) was justified with the results of in vitro character-
ization studies where the particles were shown to be safe and
efficient against S. aureus and P. aeruginosa at potential clin-
ical concentrations.
By utilizing continuous MJR, micromixing is achieved,
resulting in narrow particle size distribution. The use of
MJR increases the chance of the developed NPs to clinics
not only due to easily scalable continuous process but also
due to fact that manufacturing NPs under control conditions
ensures high manufacturing quality with the same critical
quality attributes, such as particle size, PDI, and drug loading,
at every batch. Critical quality attributes of drug delivery sys-
tems might dictate physicochemical stability and are known to
be also responsible for in vivo performance.
Results indicated that ciprofloxacin-loaded PLGA and
PCL NPs exhibited the desired release properties to reach
the therapeutic concentration (MIC of 0.25–0.99 μg/ml
against susceptible and resistant strains of P. aeruginosa)
within 24 h at the site of action to prevent any potential infec-
tion. Slower release kinetics from the PCL NPs in comparison
to PLGA is possibly due to the interaction of ciprofloxacin
with oleic acid. Ciprofloxacin is a zwitterionic substance with
two ionizable groups: carboxyl and amine groups.
Accordingly, its solubility depends on the physicochemical
properties of the aqueous solvent used. However, oleic acid,
unsaturated fatty acid, shows a lipophilic character and does
not lead to ionization of ciprofloxacin, thus pH-dependent
solubility. On the other hand, it offers interaction sites to cip-
rofloxacin, e.g., through hydrogen bonding [35, 40]. By
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Fig. 7 Particle size and PDI measurements at time points of 0 h, 3 h, 5 h,
and 24 h of PCL nanoparticles (a), concentrated PCL nanoparticles (b),
and PLGA-wow nanoparticles (c) for dose dumping test
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simultaneous deposition of PLGA and PCL NPs on the im-
plants, the concentration at the site of action can be sustained
since a biphasic release profile can be reached by physically
mixing both particles: controlled release of the antibiotic from
PLGA to reach the effective concentration at the site of action
and slow releasing PCL NPs to sustain that concentration.
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Conclusion
In many tissue engineering applications, the role of the scaf-
fold is to support tissue regeneration, which comes after
reconstructive surgery in a hostile microenvironment, in
which inflammation is present, together with high probabil-
ity of infection relapses. Depending on the extent of dam-
age, the performance of the scaffolds might remain
Fig. 11 Phalloidin (green
channel) andDAPI (blue channel)
staining confirming the
homogeneous growth and
proliferation of human
mesenchymal stromal cells
(hMSCs) on electrospun (ES)
scaffolds with and without
ciprofloxacin-loaded PLGA NPs.
The cells were cultured and im-
aged at 24-h and 8-day time
points. Scale bar = 200 μm
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suboptimal, which makes it difficult to recover suitable func-
tionality. Here-presented antibiotic-loaded polymeric NP–
integrated electrospun nanofibers aim at filling the treatment
gap by providing biomimetic, reliable, and highly effective
scaffolds with sustained drug delivery and anti-inflammatory
activity.
Results showed that ciprofloxacin-loaded PLGA and PCL
NPs were successfully prepared by two different manufactur-
ing strategies where a continuous manufacturing method
which offers unlimited scale-up was employed. Prepared par-
ticles showed high EE% and a narrow particle size distribu-
tion, which are critical for clinical applicability, among which
PCL NPs and PLGA-wow NPs were selected as potential
candidates owing to better stability. Prepared particles showed
predictable controlled release properties, which would enable
sustaining the antibiotic concentration at the site of action for
enhancing the therapy. Additionally, all the NPs were more
effective and safer against S. aureus and P. aeruginosa in
comparison to free drug. This finding suggests that the devel-
oped particles can be employed to reduce the applied dose and
eventually minimize the oral or i.v. administration of antibi-
otics after implants, since they offer local drug delivery as they
are embedded in electrospun fibers.
The current work shows that there is good potential for
application of antibiotic-loaded NP-embedded nanofiber scaf-
folds for first-line therapy of tissue engineering. The results
indicate that antibiotic-loaded NPs can be successfully applied
for use of scaffolds to deliver antibiotics locally for preventing
bacterial infections around the implant. The ciprofloxacin-
loaded NPs in electrospun scaffolds offer a better profit for
the therapy since such an approach offers the treatment and/or
prevention of infection by bacteria after implanting in com-
parison to the traditional implants. Presented data provides
solid scientific evidence for fulfilling the requirements of local
nano antibiotic delivery systems with biodegradability and
biocompatibility for a wide range of tissue engineering and
regenerative medicine applications, including tympanic ear
membranes. Further characterization of such systems, includ-
ing in vivo studies, is required to ensure successful transfer
from lab to clinical applications.
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This design is envisaged to stimulate in situ tissue regen-
eration owing to optimal tolerance, accelerated healing ow-
ing to normalized microenvironment without inflammatory
components or bacteria. Patients’ quality of life could be
remarkably improved upon implementation of this therapy
approach.
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